Our lead therapeutic candidate: IGF-MTX
We have completed a Phase I clinical trial of IGF-methotrexate (IGF-MTX) in patients with mixed solid tumors and lymphoma. The results show the following:
- Efficacy at approximately 10x lower dose than the minimum standard dose of methotrexate alone; and
- Reduced toxicity: no observable decrease in blood cell counts.
See additional information here: https://clinicaltrials.gov/ct2/show/NCT02045368
We are currently conducting a Phase 1a/2b clinical trial of IGF-MTX in myelodysplastic syndrome at the Mayo Clinic: https://clinicaltrials.gov/ct2/show/NCT03175978
- Opened a Phase 1b/2a clinical trial at Mayo Clinic in the blood cancer myelodysplastic syndrome (MDS) January 2018.
- MDS is a deadly blood cancer with no very effective treatments.
- Only two currently approved drugs for MDS, and they don’t work very well.
- IGF-MTX kills MDS cells in the laboratory and is synergistic with the most commonly used of two approved drugs.
- IGF receptors are overexpressed on MDS disease cells.
- IGF-MTX is well suited for this disease because the patients cannot tolerate any decrease in blood cells, and unlike all other cancer chemotherapy, IGF-MTX does not cause any decrease in blood cells.
We plan to open a Phase I clinical trial of a different agent to treat ovarian cancer.